Related Experiment Video
Updated: Jun 22, 2026
08:50
Deep Neuromuscular Blockade Leads to a Larger Intraabdominal Volume During Laparoscopy
Published on: June 25, 2013
Reversal of neuromuscular block
1University of Liverpool Critical Care Research Unit, School of Clinical Science, Daulby Street, Liverpool, UK. alok.srivastava@nhs.net
British Journal of Anaesthesia
|May 27, 2009
Summary
Sugammadex offers effective reversal of neuromuscular block caused by rocuronium and vecuronium, unlike traditional anticholinesterases. This new agent provides rapid antagonism without muscarinic side effects, though long-term safety data is still emerging.
Area of Science:
- Anesthesiology
- Pharmacology
Background:
- Anticholinesterases are used to reverse residual neuromuscular block but require established recovery and have side effects.
- An ideal reversal agent should be effective regardless of recovery status and lack adverse effects.
Purpose of the Study:
- To evaluate sugammadex as a novel reversal agent for neuromuscular blocking agents.
- To compare the efficacy and side effect profile of sugammadex with traditional anticholinesterases.
Main Methods:
- Sugammadex, a gamma cyclodextrin, chelates aminosteroid neuromuscular blocking agents (NMBAs) like rocuronium and vecuronium.
- Dosing of sugammadex is adjusted based on the degree of residual neuromuscular block.
Main Results:
- Sugammadex effectively antagonizes profound neuromuscular block from rocuronium and vecuronium.
- Sugammadex is ineffective against benzylisoquinolinium NMBAs.
- Reported side effects are rare, including cardiovascular events like hypotension and prolonged QT interval.
Conclusions:
- Sugammadex represents a promising alternative for reversing specific neuromuscular blocks.
- Further research is needed to fully understand the long-term safety and side effect profile of sugammadex.
Related Concept Videos
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
01:28Depolarizing Blockers: Mechanism of Action
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
01:29Neuromuscular Junction And Blockade
The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
01:11Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...